Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Ringstad, B. Jacobsen, S. Tretli, Y. Thomassen (1988)
Serum selenium concentration associated with risk of cancer.Journal of Clinical Pathology, 41
Willis CE Shamberger RJ (1971)
Selenium distribution of human cancer mortalityCrit Rev Clin Lab Sci, 2
W. Blot, J. Li, P. Taylor, Wande Guo, S. Dawsey, Guo-qing Wang, Chung Yang, S. Zheng, M. Gail, G. Li, Yu Yu, B. Liu, J. Tangrea, Yu Sun, Fu-sheng Liu, J. Fraumeni, Yousheng Zhang, Bing Li (1993)
Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population.Journal of the National Cancer Institute, 85 18
M. Nelson, J. Einspahr, D. Alberts, C. Balfour, J. Wymer, K. Welch, S. Salasche, J. Bangert, T. Grogan, Paul Bozzo (1994)
Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers.Cancer letters, 85 1
Food and Nutrition Board Subcommittee on the Tenth Edition of the RDAs (1989)
Tenth Edition
A. Nomura, L. Heilbrun, Morris Js, Stemmermann Gn (1987)
Serum selenium and the risk of cancer, by specific sites: case-control analysis of prospective data.Journal of the National Cancer Institute, 79 1
P. Knekt, A. Aromaa, J. Maatela, G. Alfthan, R. Aaran, M. Hakama, T. Hakulinen, R. Peto, L. Teppo (1990)
Serum selenium and subsequent risk of cancer among Finnish men and women.Journal of the National Cancer Institute, 82 10
R. Cook, V. Farewell (1996)
Multiplicity Considerations in the Design and Analysis of Clinical TrialsJournal of The Royal Statistical Society Series A-statistics in Society, 159
G. Fex, B. Pettersson, B. Åkesson (1987)
Low plasma selenium as a risk factor for cancer death in middle-aged men.Nutrition and cancer, 10 4
S. Pocock, N. Geller, A. Tsiatis (1987)
The analysis of multiple endpoints in clinical trials.Biometrics, 43 3
M. Frick, Olli Elo, K. Haapa, O. Heinonen, P. Heinsalmi, Pekka Helo, J. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, H. Mäenpää, M. Mälkönen, M. Mänttäri, S. Norola, A. Pasternack, J. Pikkarainen, M. Romo, T. Sjöblom, E. Nikkilä (1987)
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.The New England journal of medicine, 317 20
W. Willett, M. Stampfer (1988)
Selenium and cancer.British Medical Journal, 297
Turnbull BW Jennison C (1989)
Interim analysesJ R Stat Soc B, 51
J. Salonen, R. Salonen, R. Lappeteläinen, P. Mäenpää, G. Alfthan, P. Puska (1985)
Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case-control analysis of prospective data.British Medical Journal (Clinical research ed.), 290
R. Peto, M. Pike, P. Armitage, N. Breslow, D. Cox, S. Howard, N. Mantel, K. McPherson, J. Peto, Peter Smith (1976)
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.British Journal of Cancer, 34
I. Peleg, Steve Morris, C. Hames (1985)
Is serum selenium a risk factor for cancer?Medical Oncology and Tumor Pharmacotherapy, 2
Milne Ja (1985)
Effect of selenium on virally induced and transplantable tumor models., 44
Elo O Frick MH (1987)
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemiaN Engl J Med, 317
Palmer IS Olson OE (1975)
Modification of the official fluorometric method for selenium in plantsJ Assoc Off Anal Chem, 58
Combs GF Jr (1994)
Risk Assessment of Essential Elements
O. Olson, I. Palmer, E. Cary (1975)
Modification of the official fluorometric method for selenium in plantsJournal of AOAC International, 58
Combs GF Jr (1995)
Biochemistry and Molecular Biology of Selenium
Ip C (1986)
The chemopreventive role of selenium in carcinogenesisJ Am Coll Toxicol, 5
G. Comstock, T. Bush, K. Helzlsouer (1992)
Serum retinol, beta-carotene, vitamin E, and selenium as related to subsequent cancer of specific sites.American journal of epidemiology, 135 2
Xiaolong Luo, B. Turnbull, H. Cai, L. Clark (1994)
Regression for censored survival data with lag effectsCommunications in Statistics-theory and Methods, 23
Aromaa A Knekt P (1990)
Serum selenium and subsequent risk of cancer among Finnish men and womenJ Natl Cancer Inst, 82
Morris JS Garland M (1995)
Prospective study of toenail selenium and cancer among womenJ Natl Cancer Inst, 87
Eystein Glattre, Yngvar Thomassen, S. Thoresen, Tor Haldorsen, P. Lund-Larsen, L. Theodorsen, Jan Aaseth (1989)
Prediagnostic serum selenium in a case-control study of thyroid cancer.International journal of epidemiology, 18 1
R. Coates, N. Weiss, J. Daling, J. Morris, R. Labbé (1988)
Serum levels of selenium and retinol and the subsequent risk of cancer.American journal of epidemiology, 128 3
Graham GF Clark LC (1986)
The Third International Symposium on Selenium in Biology and Medicine
S. Palmer (1990)
Recommended dietary allowances, tenth edition.European journal of clinical nutrition, 44 Suppl 2
M. Gailani, D. Leffell, A. Ziegler, E. Gross, D. Brash, A. Bale (1996)
Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma.Journal of the National Cancer Institute, 88 6
M. Pahor, J. Guralnik, L. Ferrucci, M. Corti, M. Salive, J. Cerhan, R. Wallace, R. Havlik (1996)
Calcium-channel blockade and incidence of cancer in aged populationsThe Lancet, 348
H. Thompson, A. Wilson, Junxuan Lu, Meenakshi Singh, Cheng Jiang, P. Upadhyaya, K. El-Bayoumy, C. Ip (1994)
Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line.Carcinogenesis, 15 2
Valkeila E Virtamo J (1987)
Serum selenium and risk of cancerCancer, 60
L. McShane, L. Clark, G. Combs, B. Turnbull (1991)
Reporting the accuracy of biochemical measurements for epidemiologic and nutrition studies.The American journal of clinical nutrition, 53 6
F. Kok, A. Bruijn, A. Hofman, R. Vermeeren, H. Valkenburg (1987)
Is serum selenium a risk factor for cancer in men only?American journal of epidemiology, 125 1
Taylor PR Li JY (1993)
Nutrition intervention trials in Linxian, ChinaJ Natl Cancer Inst, 85
White DA Schrauzer GN (1977)
Cancer mortality correlation studies, IIIBioinorganic Chem, 7
P. Knekt, A. Aromaa, J. Maatela, G. Alfthan, R. Aaran, L. Teppo, M. Hakama (1988)
Serum vitamin E, serum selenium and the risk of gastrointestinal cancerInternational Journal of Cancer, 42
Thead WJ Schrauzer GN (1971)
Interpretation of the methylene blue reduction test of human plasma and the possible cancer protecting effect of seleniumExperientia, 27
J. Virtamo, E. Valkeila, G. Alfthan, S. Punsar, J. Huttunen, M. Karvonen (1987)
Serum selenium and risk of cancer. A prospective follow‐up of nine yearsCancer, 60
Tannock IF (1996)
False-positive results in clinical trialsJ Natl Cancer Inst, 88
Leffell DJ Gailani MR (1996)
Relationship between sunlight exposure and a key genetic alteration in basal cell carcinomaJ Natl Cancer Inst, 88
R. Shamberger, D. Frost (1969)
Possible protective effect of selenium against human cancer.Canadian Medical Association journal, 100 14
S. Schober, G. Comstock, K. Helsing, R. Salkeld, J. Morris, Agatha Rider, R. Brookmeyer (1987)
Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk.American journal of epidemiology, 126 6
Graham GF Clark LC (1984)
Plasma selenium and skin neoplasmsNutr Cancer, 6
R. Burk, K. Hill (1993)
Regulation of selenoproteins.Annual review of nutrition, 13
P. Brandt, R. Goldbohm, P. Veer, P. Bode, E. Dorant, R. Hermus, F. Sturmans (1993)
A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer.Journal of the National Cancer Institute, 85 3
State Cancer Control and Data Program National Cancer Institute (1992)
Cancer Mortality by Pentad 1953-1957 to 1983-1987
Clark Lc (1985)
The epidemiology of selenium and cancer., 44
I. Tannock (1996)
False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons.Journal of the National Cancer Institute, 88 3-4
W. Willett, J. Morris, S. Pressel, JamesO Taylor, B. Polk, M. Stampfer, B. Rosner, K. Schneider, C. Hames (1983)
PREDIAGNOSTIC SERUM SELENIUM AND RISK OF CANCERThe Lancet, 322
C. Ip (1986)
The chemopreventive role of selenium in carcinogenesis.Advances in Experimental Medicine and Biology, 206
M. Garland, J. Morris, M. Stampfer, G. Colditz, V. Spate, C. Baskett, B. Rosner, F. Speizer, W. Willett, D. Hunter (1995)
Prospective study of toenail selenium levels and cancer among women.Journal of the National Cancer Institute, 87 7
Salonen R Salonen JT (1985)
Risk of cancer in relation to serum concentrations of selenium and vitamins A and EBMJ, 290
M. Menkes, G. Comstock, J. Vuilleumier, K. Helsing, Agatha Rider, R. Brookmeyer (1986)
Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer.The New England journal of medicine, 315 20
Medina D Ip C (1987)
Cellular and Molecular Biology of Breast Cancer
Heilbrun LK Nomura A (1987)
Serum selenium and the risk of cancer, by specific sitesJ Natl Cancer Inst, 79
Turnbull BW Abu-Libdeh H (1990)
Analysis of multi-type recurrent events in longitudinal studiesBiometrics, 46
El-Bayoumy K (1991)
Practice of Oncology
Comstock GW Schober SE (1987)
Serologic precursors of cancerAm J Epidemiol, 126
The LRC Study Group (1984)
The Lipid Research Clinics Coronary Primary Prevention Trial resultsJAMA, 251
L. Adolf (1964)
RECOMMENDED DIETARY ALLOWANCES.Clinical pediatrics, 3
H. Abu-Libdeh, B. Turnbull, L. Clark (1990)
Analysis of multi-type recurrent events in longitudinal studies; application to a skin cancer prevention trial.Biometrics, 46 4
K. Rothman (1990)
No Adjustments Are Needed for Multiple ComparisonsEpidemiology, 1
W. Allaway, J. Kubota, F. Losee, M. Roth (1968)
Selenium, molybdenum, and vanadium in human blood.Archives of environmental health, 16 3
G. Combs, S. Combs (1986)
The role of selenium in nutrition
Goldbohm R van den Brandt P (1993)
A prospective cohort study of toenail selenium levels and risk of gastrointestinal cancerJ Natl Cancer Inst, 85
Fleming J Lanfear J (1994)
The selenium metabolite selenodiglutathione induces p53 and apoptosisCarcinogenesis, 15
J. Salonen, G. Alfthan, J. Huttunen, P. Puska (1984)
Association between serum selenium and the risk of cancer.American journal of epidemiology, 120 3
J. Li, P. Taylor, Bing Li, S. Dawsey, Guo-qing Wang, A. Ershow, Wande Guo, S. Liu, Chung Yang, Q. Shen, Wen Wang, S. Mark, X. Zou, P. Greenwald, Y. Wu, W. Blot (1993)
Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia.Journal of the National Cancer Institute, 85 18
L. Clark, K. Cantor, W. Allaway (1991)
Selenium in forage crops and cancer mortality in U.S. counties.Archives of environmental health, 46 1
Yin S Yang GQ (1989)
Studies of safe maximal daily dietary Se-intake in a seleniferous area of ChinaJ Trace Elem Electrolytes Health Dis, 3
Abstract Objective. —To determine whether a nutritional supplement of selenium will decrease the incidence of cancer. Design. —A multicenter, double-blind, randomized, placebo-controlled cancer prevention trial. Setting. —Seven dermatology clinics in the eastern United States. Patients. —A total of 1312 patients (mean age, 63 years; range, 18-80 years) with a history of basal cell or squamous cell carcinomas of the skin were randomized from 1983 through 1991. Patients were treated for a mean (SD) of 4.5 (2.8) years and had a total follow-up of 6.4 (2.0) years. Interventions. —Oral administration of 200 μg of selenium per day or placebo. Main Outcome Measures. —The primary end points for the trial were the incidences of basal and squamous cell carcinomas of the skin. The secondary end points, established in 1990, were all-cause mortality and total cancer mortality, total cancer incidence, and the incidences of lung, prostate, and colorectal cancers. Results. —After a total follow-up of 8271 person-years, selenium treatment did not significantly affect the incidence of basal cell or squamous cell skin cancer. There were 377 new cases of basal cell skin cancer among patients in the selenium group and 350 cases among the control group (relative risk [RR], 1.10; 95% confidence interval [CI], 0.95-1.28), and 218 new squamous cell skin cancers in the selenium group and 190 cases among the controls (RR, 1.14; 95% CI, 0.93-1.39). Analysis of secondary end points revealed that, compared with controls, patients treated with selenium had a nonsignificant reduction in all-cause mortality (108 deaths in the selenium group and 129 deaths in the control group [RR, 0.83; 95% CI, 0.63-1.08]) and significant reductions in total cancer mortality (29 deaths in the selenium treatment group and 57 deaths in controls [RR, 0.50; 95% CI, 0.31-0.80]), total cancer incidence (77 cancers in the selenium group and 119 in controls [RR, 0.63; 95% CI, 0.47-0.85]), and incidences of lung, colorectal, and prostate cancers. Primarily because of the apparent reductions in total cancer mortality and total cancer incidence in the selenium group, the blinded phase of the trial was stopped early. No cases of selenium toxicity occurred. Conclusions. —Selenium treatment did not protect against development of basal or squamous cell carcinomas of the skin. However, results from secondary end-point analyses support the hypothesis that supplemental selenium may reduce the incidence of, and mortality from, carcinomas of several sites. These effects of selenium require confirmation in an independent trial of appropriate design before new public health recommendations regarding selenium supplementation can be made. References 1. Shamberger RJ, Frost DV. Possible protective effect of selenium against human cancer . Can Med Assoc J . 1969;100:682. 2. Shamberger RJ, Willis CE. Selenium distribution of human cancer mortality . Crit Rev Clin Lab Sci . 1971;2:211-221.Crossref 3. Schrauzer GN, Thead WJ. Interpretation of the methylene blue reduction test of human plasma and the possible cancer protecting effect of selenium . Experientia . 1971;27:1069-1071.Crossref 4. Combs GF Jr, Combs S. The Role of Selenium in Nutrition . New York, NY: Academic Press; 1986. 5. Burk RF, Hill KE. Regulation of selenoproteins . Annu Rev Nutr . 1993;13:65-81.Crossref 6. Combs GF Jr. Essentiality and toxicity of selenium: a critique of the recommended dietary allowance and the reference dose . In: Mertz W, Abernathy CO, Olin SS, eds. Risk Assessment of Essential Elements . Washington, DC: ILSI Press; 1994:167-183. 7. Subcommittee on the Tenth Edition of the RDAs, Food and Nutrition Board, Commission on Life Sciences, National Research Council. Recommended Dietary Allowances , Tenth Edition . Washington, DC: National Academy Press; 1989. 8. Combs GF Jr. Selenium and cancer . In: Wang Z, ed. Biochemistry and Molecular Biology of Selenium . Beijing, China: Chinese Academy of Science; 1995. 9. Milner JA. Effect of selenium on virally induced and transplantable tumor models . Fed Proc . 1985; 44:2568-2572. 10. Ip C. The chemopreventive role of selenium in carcinogenesis . J Am Coll Toxicol . 1986;5:7-20Crossref 11. Ip C, Medina D. Current concept of selenium and mammary tumorigenesis . In: Medina D, Kidwell W, Heppner G, Anderson EP, eds. Cellular and Molecular Biology of Breast Cancer . New York, NY: Plenum Press; 1987:479. 12. El-Bayoumy K. The role of selenium in cancer prevention . In: De Vita VT, Hellman S, Rosenberg SS, eds. Practice of Oncology . 4th ed. Philadelphia, Pa: JB Lippincott; 1991:1-15. 13. Schrauzer GN, White DA, Schneider CJ. Cancer mortality correlation studies, III . Bioinorganic Chem . 1977;7:23-34.Crossref 14. Clark LC, Cantor KP, Allaway WH. Selenium in forage crops and cancer mortality in US counties . Arch Environ Health . 1991;46:37-42.Crossref 15. Clark LC. The epidemiology of selenium and cancer . Fed Proc . 1985;44:2584-2590. 16. Salonen JT, Alfthan G, Huttunen JK, Puska P. Association between serum selenium and the risk of cancer . Am J Epidemiol . 1984;120:342-349. 17. Salonen JT, Salonen R, Lappeteläinen R, Mäenpää PH, Alfthan G, Puska P. Risk of cancer in relation to serum concentrations of selenium and vitamins A and E . BMJ . 1985;290:417-420.Crossref 18. Willett W, Polk B, Morris S, et al. Prediagnostic serum selenium and risk of cancer . Lancet . 1983;2:130-134.Crossref 19. Kok FJ, De Bruijn AM, Hofman A, Vermeeren R, Valkenburg HA. Is serum selenium a risk factor for cancer in men only? Am J Epidemiol . 1987;125:12-16. 20. Virtamo J, Valkeila E, Alfthan G, Punsar S, Huttunen JK, Karvonen MJ. Serum selenium and risk of cancer . Cancer . 1987;60:145-148.Crossref 21. van den Brandt P, Goldbohm R, van't Veer P, et al. A prospective cohort study of toenail selenium levels and risk of gastrointestinal cancer . J Natl Cancer Inst . 1993;85:224-229.Crossref 22. Peleg I, Morris S, Hames CG. Is serum selenium a risk factor for cancer? Med Oncol Tumor Pharmacother . 1985;2:157-163. 23. Knekt P, Aromaa A, Maatela J, et al. Serum selenium and subsequent risk of cancer among Finnish men and women . J Natl Cancer Inst . 1990;82:864-868.Crossref 24. Glattre E, Thomassen Y, Thoresen SO, et al. Prediagnostic serum selenium in a case-control study of thyroid cancer . Int J Epidemiol . 1989;18:45-49.Crossref 25. Fex G, Pettersson B, Akesson B. Low plasma selenium as a risk factor for cancer death in middleaged men . Nutr Cancer . 1987;10:221-229.Crossref 26. Menkes MS, Comstock GW, Vuilleumier JP, Helsing KJ, Rider AA, Brookmeyer RP. Serum betacarotene, vitamins A and E, selenium, and the risk of lung cancer . N Engl J Med . 1986;315:1250-1254.Crossref 27. Garland M, Morris JS, Stampfer MJ, et al. Prospective study of toenail selenium and cancer among women . J Natl Cancer Inst . 1995;87:497-505.Crossref 28. Schober SE, Comstock GW, Helsing KJ, et al. Serologic precursors of cancer . Am J Epidemiol . 1987;126:1033-1041. 29. Nomura A, Heilbrun LK, Morris JS, Stemmermann GN. Serum selenium and the risk of cancer, by specific sites . J Natl Cancer Inst . 1987;79:103-108. 30. Knekt P, Aromaa A, Maatela J, et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer . Int J Cancer . 1988;42:846-850.Crossref 31. Ringstad J, Jacobsen BK, Tretli S, Thomassen Y. Serum selenium concentration associated with risk of cancer . J Clin Pathol . 1988;41:454-457.Crossref 32. Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe RF. Serum levels of selenium and retinol and the subsequent risk of cancer . Am J Epidemiol . 1988; 128:515-523. 33. Clark LC, Graham GF, Crouse RG, Grimson R, Hulka B, Shy CM. Plasma selenium and skin neoplasms . Nutr Cancer . 1984;6:13-21.Crossref 34. Clark LC, Graham GF, Turnbull BW, Bray J, Hulka B, Shy CM. Non-melanoma skin cancer and plasma selenium: a prospective cohort study . In: Combs GF Jr, Spallholz JE, Levander OA, Oldfield JE, eds. The Third International Symposium on Selenium in Biology and Medicine . Westport, Conn: AVI Publishing Co; 1986:1122-1135. 35. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China . J Natl Cancer Inst . 1993;85:1483-1492.Crossref 36. Li JY, Taylor PR, Li B. Nutrition intervention trials in Linxian, China . J Natl Cancer Inst . 1993; 85:1492-1498.Crossref 37. Olson OE, Palmer IS, Cary EE. Modification of the official fluorometric method for selenium in plants . J Assoc Off Anal Chem . 1975;58:117-126. 38. McShane LM, Clark LC, Combs GF Jr, Turnbull BW. Reporting the accuracy of biochemical measurements for epidemiologic and nutrition studies . Am J Clin Nutr . 1991;53:1354-1360. 39. Abu-Libdeh H, Turnbull BW, Clark LC. Analysis of multi-type recurrent events in longitudinal studies . Biometrics . 1990;46:1017-1023.Crossref 40. Luo X, Turnbull BW, Cai H, Clark LC. Regression for censored survival data with lag effects . Commun Stat . 1994;23:3417-3438.Crossref 41. Allaway WH, Kubota J, Losee F, Roth M. Selenium, molybdenum and vanadium in human blood . Arch Environ Health . 1968;16:342-348.Crossref 42. National Cancer Institute, State Cancer Control and Data Program. Cancer Mortality by Pentad 1953-1957 to 1983-1987 . Bethesda, Md: National Institutes of Health; 1992. 43. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers . Cancer Lett . 1994;85:23-29.Crossref 44. Gailani MR, Leffell DJ, Ziegler A, Gross EG, Brash DE, Bale AE. Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma . J Natl Cancer Inst . 1996;88:349-354.Crossref 45. Lanfear J, Fleming J, Wu L, Webster G, Harrison PR. The selenium metabolite selenodiglutathione induces p53 and apoptosis . Carcinogenesis . 1994; 15:1378-1392.Crossref 46. Yang GQ, Yin S, Zhou R. Studies of safe maximal daily dietary Se-intake in a seleniferous area of China . J Trace Elem Electrolytes Health Dis . 1989;3:123-130. 47. Thompson JH, Wilson A, Lu J, et al. Comparison of the effects of an organic and inorganic form of selenium on a mammary carcinoma cell line . Carcinogenesis . 1994;15:183-186.Crossref 48. Pahor M, Gurainik JM, Ferrucci L, et al. Calcium channel blockade and incidence of cancer in aged populations . Lancet . 1996;348:493-497.Crossref 49. The LRC Study Group. The Lipid Research Clinics Coronary Primary Prevention Trial results . JAMA . 1984;251:351-364.Crossref 50. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia . N Engl J Med . 1987;317:1237-1245.Crossref 51. Comstock GW, Bush TL, Helzlsouer K. Serum retinol, beta-carotene, vitamin E and selenium as related to subsequent cancer of specific sites . Am J Epidemiol . 1992;135:115-121. 52. Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials . Biometrics . 1987;43:487-498.Crossref 53. Rothman KJ. No adjustments are needed for multiple comparisons . Epidemiology . 1990;1:43-46.Crossref 54. Tannock IF. False-positive results in clinical trials . J Natl Cancer Inst . 1996;88:206-207.Crossref 55. Cook RJ, Farewell VT. Multiplicity considerations in the design and analysis of clinical trials . J R Stat Soc A . 1996;159:93-110.Crossref 56. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, I: introduction and design . Br J Cancer . 1976;34:585-612.Crossref 57. Cox DR. In Discussion: Jennison C, Turnbull BW. Interim analyses . J R Stat Soc B . 1989;51:338. 58. Jennison C, Turnbull BW. Interim analyses . J R Stat Soc B . 1989;51:305-361.
JAMA – American Medical Association
Published: Dec 25, 1996
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.